Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences develops and commercializes medicines for HIV, viral hepatitis, COVID-19 and cancer. Company updates regularly cover product sales and operating results, HIV franchises such as Biktarvy, Yeztugo and lenacapavir, and clinical or regulatory activity for investigational HIV regimens that combine established antiretroviral agents with newer mechanisms.
Recurring developments also include oncology pipeline expansion through Kite cell-therapy programs, the completed acquisition of Arcellx and its investigational BCMA-directed CAR T-cell therapy anitocabtagene autoleucel for multiple myeloma, collaboration activity using real-world evidence in oncology R&D, shareholder matters, and capital-structure disclosures tied to material agreements and acquisitions.
Kite, a Gilead Company, and Arcellx, Inc. announced operational updates on their anito-cel multiple myeloma program. They shared the iMMagine-3 trial design, manufacturing details, and plans to present data from the iMMagine-1 trial. Anito-cel is a BCMA CAR T cell therapy for relapsed/refractory multiple myeloma.
Gilead's FOCUS Program, launched in 2010, has been instrumental in early HIV detection and linkage to care. By partnering with state and local officials, healthcare providers, and organizations, the program has significantly reduced late-stage HIV diagnoses in underserved populations across the United States.
Gilead's partnership with the government of Mauritius has helped in the elimination of Hepatitis C in the country. By providing low-cost treatment and working with high-prevalence regions, the company has contributed to the success of patients like James, who is now free from the disease. The government's commitment and public-private partnerships have been instrumental in the progress towards eradicating Hepatitis C in the region.
Gilead Sciences, Inc. and Kite, a Gilead Company, will present 18 abstracts at the 2024 ASCO Annual Meeting, showcasing their commitment to developing innovative cancer treatments. The data cover a broad range of cancers, including lung, breast, and gastrointestinal, with highlights on Trodelvy in NSCLC, gastrointestinal pipeline progress, and new CAR T-cell therapy data. The company continues to focus on transforming cancer treatment through groundbreaking research.
Forbes has recognized Gilead as one of America's Best Employers for Diversity. The company's commitment to inclusion and diversity is highlighted, reflecting positive feedback from employees and the community. Gilead Sciences, a biopharmaceutical company, aims to innovate medicines for unmet medical needs globally.
Gilead Sciences, Inc. (Nasdaq: GILD) executives will be speaking at several upcoming investor conferences, showcasing the company's commitment to advancing innovative medicines for life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. The live webcasts and replays will be available on the company's investors page. Gilead operates globally with headquarters in Foster City, California.
Summary not available.
Summary not available.
Summary not available.
Summary not available.